Atractylenolide‐I attenuates oxidative stress and Parkinson's disease–related pathology by activating the SIRT1/PGC‐1α/Nrf2 signaling axis (Gao et al. 2024). The gene discussed is PPARGC1A; the disease is Parkinson disease.